Document is current
Any future updates will be listed below
-
Authors
Quesnel-Vallières, Mathieu
Schultz, David C.
Orlenko, Alena
Lo, Yancy
Moore, Jason
Ritchie, Marylyn
Roth, David
Carroll, Martin
Barash, Yoseph
Lynch, Kristen W. https://orcid.org/0000-0002-0120-8079
Cherry, Sara
-
Funding
Funding for this research was provided by:
National Cancer Institute (U01 CA232563, U01 CA232563, U01 CA232563)
National Institute of General Medical Sciences (R35 GM118048)
U.S. Department of Veterans Affairs (I01BX004662)
- License Information
-
More Information
Article History
Accepted: 5 September 2024
First Online: 24 September 2024
Declarations
:
: M.Q.V., Y.B., and K.W.L. were supported by U01 CA232563; K.W.L. was also supported by R35 GM118048; M.C. is supported by VA Merit Award I01BX004662.
: The authors declare that they have no conflicts of interest.
: All samples were collected and experiments undertaken with the understanding and written consent of each subject in accordance with IRB approval #703185.
: All sequencing data used are publicly available as stated in the Transcriptomic Analysis section.
: Code is available at .
: The study methodology conformed to the standards set by the Declaration of Helsinki and were approved by the Penn institutional review board (IRB) committee (IRB approval #703185 since 12/2001).
: M.Q.V., Y.B., K.W.L., and S.C. conceived of the project; designed, directed, and carried out the transcriptomic analysis; and wrote the manuscript. D.C.S. and Y.L. cultured patient samples and carried out the trametinib screening. A.O., J.M. and M.R. carried out analyses of screening and other patient data. D.R. and M.C. recruited patients and collected samples.
